Skip to main content
TipRanks
Go Ultimate75% OFF

Bruker (BRKR) AI Stock Analysis

493 Followers
BRKR

Bruker

(NASDAQ:BRKR)

Select Model
Rating:61Neutral
Price Target:$67.00â–²(8.78% Upside)
Action:reiterated
Date:11/05/26

The score is held back mainly by weakened profitability (GAAP losses and sharply compressed operating margins) despite strong revenue growth and improved free cash flow. Technicals are supportive with the stock in an uptrend and momentum indicators constructive. Guidance and commentary add confidence around non-GAAP margin and EPS improvement, but valuation remains challenged due to the negative P/E and only a modest dividend yield.

Positive Factors
Recurring Revenue ModelBruker combines upfront instrument sales with recurring service, software and consumables revenue from its installed base. That mix can improve customer retention and revenue visibility, while complex workflows and uptime needs support ongoing monetization after each system is placed.
Negative Factors
Severely Compressed ProfitabilityBruker's strong revenue growth is not yet translating into durable GAAP profitability. The swing to a TTM net loss and near-zero EBIT margin reduces earnings resilience, limits internal funding capacity and makes successful execution of the recovery plan important to restoring financial quality.

Bruker Key Performance Indicators (KPIs)

Revenue by GeographyShows where Bruker earns sales across regions, highlighting which markets drive growth and how diversified the company is. Reveals exposure to regional economic slowdowns, currency swings, and localized demand for scientific instruments and services.

$0.00$250.00M$500.00M$750.00M$1.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

The geographic mix is shifting: North America and Europe (ex‑Germany) are now the steady engines behind revenue and non‑GAAP margin improvement, while China/APAC remain choppy—China plunged from prior highs into early‑2026 then partially rebounded, keeping regional growth uneven. Management’s commentary lines up: strong deep‑tech and semiconductor bookings outside China underpin medium‑term upside, but long lead times, FX/tariff effects and a disclosed ~$20M Q3→Q4 timing shift mean organic growth will be lumpy quarter to quarter despite improving margins.

Data provided by:The Fly

Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%BRKR+44.99%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.41B
Dividend Yield
0.32%
Average Volume (3M)
2.31M
Price to Earnings (P/E)
-56.0
Beta (1Y)
1.17
Revenue Growth
2.16%
EPS Growth
-604.24%
Country
US
Employees
11,085
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments...

How the Company Makes Money

Bruker makes money primarily by selling scientific and diagnostic instruments and then generating recurring revenue from the installed base through services, software, and consumables. Key revenue streams typically include: (1) Instrument and system...

Bruker Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:9.01%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Bruker reported significant margin expansion, 24.4% non-GAAP EPS growth, improved free cash flow, debt reduction, sustained bookings above one, strong China and semiconductor metrology bookings, and reaffirmed full-year guidance. These positives were partly offset by modest organic revenue growth, BSI revenue pressure from semiconductor pushouts, weakness in selected academic and government and industrial markets, a $175 million Spatial Biology goodwill impairment, and a GAAP loss. Management expressed increased confidence in the fourth quarter and meaningful growth and margin improvement in 2027.

Positive Updates

Third-Quarter Revenue and EPS Growth
Third-quarter 2026 reported revenue increased 1.6% year over year to $874 million, with organic growth of 0.7%. Non-GAAP diluted EPS was $0.56, up 24.4% from $0.45 in the third quarter of 2025.

Negative Updates

Organic Revenue Growth Remained Modest
Although reported revenue increased 1.6% in the third quarter, organic revenue growth was only 0.7%. For the first nine months of 2026, revenue increased 3.1% to $2.54 billion, while organic revenue was essentially flat.

Company Guidance

For fiscal year 2026, Bruker expects reported revenue of $3.52 billion-$3.56 billion, representing reported growth of 2.5%-3.5%, organic revenue growth of 1%-2%, contribution from acquisition to approximately 1.5%, currency to be approximately neutral, non-GAAP operating margin expansion of 250-300 basis points, and non-GAAP EPS of $2.10-$2.15, up 15%-17%; for the fourth quarter, it expects organic revenue to grow in the lower mid-single digits percentage year over year, with meaningful sequential and year-over-year increases in operating margin and EPS, a likely $1 billion in revenue quarter, and operating margin stepping up to the high teens, while for fiscal year 2027 it is committed to double-digit EPS growth, is seeking greater than 100 basis points of further operating margin expansion, and expects organic growth at least to the lower mid-single digits; BMID is expected to be a high single-digit growth area long term, and Bruker targets reducing its tax rate by at least 50 basis points on a year-over-year basis in 2027.

Bruker Financial Statement Overview

Summary

Mixed fundamentals. Revenue is strong (TTM up 38.6%) and free cash flow rebounded meaningfully (TTM FCF ~$245M), and leverage has improved (debt-to-equity ~0.80x TTM). However, profitability has deteriorated sharply with a GAAP loss in TTM (net margin -2.0%) and very thin operating profitability (~0.5% EBIT margin TTM), making earnings normalization the key financial risk.

Income Statement

44Neutral

Balance Sheet

58Neutral

Cash Flow

63Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.51B3.44B3.37B2.96B2.53B2.42B
Gross Profit1.68B1.58B1.65B1.51B1.31B1.21B
EBITDA123.20M302.60M438.60M675.50M518.70M497.00M
Net Income-123.40M-8.60M113.10M427.20M296.60M277.10M
Balance Sheet
Total Assets5.83B6.24B5.81B4.25B3.61B3.65B
Cash, Cash Equivalents and Short-Term Investments167.00M298.80M183.40M488.30M645.50M1.17B
Total Debt1.71B2.04B2.25B1.38B1.27B1.39B
Total Liabilities3.49B3.73B3.99B2.84B2.48B2.57B
Stockholders Equity2.29B2.46B1.78B1.38B1.11B1.07B
Cash Flow
Free Cash Flow244.70M13.90M136.00M243.20M145.20M190.40M
Operating Cash Flow341.80M134.10M251.30M350.10M274.40M282.40M
Investing Cash Flow-193.20M-196.50M-1.76B-326.00M-251.60M-192.40M
Financing Cash Flow-333.40M135.10M1.23B-193.40M-415.30M318.70M

Bruker Technical Analysis

Technical Analysis SentimentPositive
Last Price61.59

Price Trends

50DMA59.47Positive
100DMA59.11Positive
200DMA50.75Positive

Market Momentum

MACD0.84Negative
RSI52.53Neutral
STOCH44.63Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 61.59 is above the 20-day moving average (MA) of 59.69, above the 50-day MA of 59.47, and above the 200-day MA of 50.75, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 52.53 is Neutral, neither overbought nor oversold. The STOCH value of 44.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.

Bruker Risk Analysis

Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution.Q4, 2025
2.The Series A Mandatory Convertible Preferred Stock may adversely affect the market price of our common stock.Q4, 2025
3.Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future.Q4, 2025

Bruker Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BRKR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GEHCGEHC79Outperform$37.54B17.5119.85%0.17%6.87%-2.26%
BIOBIO78Outperform$9.86B9.6014.07%―1.38%―
BRKRBRKR61Neutral$9.41B-56.04-5.15%0.32%2.16%-604.24%
CTKBCTKB53Neutral$763.78M-9.27-24.74%―5.50%-524.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PACBPACB44Neutral$613.34M-4.67604.22%―4.41%74.75%
QTRXQTRX36Underperform$139.11M-1.24-42.99%―13.78%-1.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%BRKRBIOPACBQTRXCTKBGEHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BRKR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BRKRBruker Corporation61.5920.0048.08%
BIOBio-Rad Laboratories366.3662.3020.49%
PACBPacific Biosciences1.960.3924.84%
QTRXQuanterix2.93-2.60-47.02%
CTKBCytek Biosciences, Inc.5.840.5510.40%
GEHCGe Healthcare Technologies Inc.83.0212.5317.78%

Bruker Corporate Events

Business Operations and StrategyFinancial Disclosures

Bruker Completes Reorganization and Updates Segment Reporting

Neutral
Nov 5, 2026

Effective July 1, 2026, Bruker completed a reorganization intended to streamline its structure and support decision-making, accountability, customer focus and innovation. The company replaced its previous four-segment reporting structure with BSI BIO...

Dividends

Bruker Declares Quarterly Dividend on Preferred Shares

Positive
Oct 29, 2026

On October 29, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, with a par value of $0.01 per share. The dividend is payable on Decemb...

Dividends

Bruker Board Declares Quarterly Cash Dividend for Shareholders

Positive
Aug 14, 2026

On August 14, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $0.05 per share on its common stock, with a par value of $0.01 per share. The dividend is scheduled to be paid on October 7, 2026, to shareholders of re...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026